- Oslo Cancer Cluster - http://oslocancercluster.no -

Breakthrough Agreement for Phoenix Solutions

A new exciting collaboration among two Oslo Cancer Cluster members has been initiated. GE Healthcare has agreed to be the manufacturer of the target drug delivery platform ACT, made by Phoenix Solutions.

Early Christmas Present
As an early Christmas present to each other the two companies announced that they had signed an agreement securing manufacturing for ACT, short for Acoustic Cluster Therapy, a technology platform for targeted drug delivery. CEO at Phoenix Solutions, Per Sontum, emphasized the importance of gaining a manufacturer that had experience with similar products.

“We are excited to sign this agreement and get GE on board as contract manufacturer of our product. With more than 20 years of experience producing Sonazoid and Optison, GE`s Oslo organization is the world leading site for the manufacturing of this class of pharmaceuticals.”

From GE`s Womb
The collaboration, however, is not totally out of the blue. Phoenix Solutions sprung out from GE Healthcare in 2013. GE`s General Manager for Norway, Bjørn Fuglaas believes this tie between the two companies is an advantage:

“We are very pleased that Phoenix has chosen to work with GE for this project, which is in line with the expectations we had when the company was spun out of GE in 2013. This is an area of interest and we believe GE to be uniquely positioned in this field given existing and strong capabilities within production of disperse pharmaceuticals, and microbubbles [1] in particular”, he says.

This agreement also secures what is called Good manufacturing practice (GMP) [2] for Phoenix Solutions. Making their product and company a safer potential for investors and further along in their development than time should suggest.

A Very Promising ACT
ACT is a special and interesting targeting device. It is an ultrasound mediated drug delivery system that specializes in beating the vascular barrier [3]. It has a wide range of therapeutically useful applications, but Its primary use being the ability to deliver sufficiently high concentrations of drug to the tumor without contaminating its surroundings. Phoenix thinks ACT is a promising targeting system for pancreatic, liver, triple negative breast and prostate cancers, and has extremely promising pre-clinical results so far.